

Full Length Research Paper

Morphine is an exogenous ligand for MrgX2, a G protein-coupled receptor for cortistatin

Natsuyo Akuzawa¹, Hideru Obinata², Takashi Izumi² and Shigeki Takeda^{1*}¹Department of Nano-Material Systems, Graduate School of Engineering, Gunma University, 1-5-1 Tenjin-cho, Kiryu, Gunma 376-8515, Japan.²Department of Molecular Biochemistry, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.

Accepted 17 September, 2017

MrgX2 is reported to be expressed in a specific subset of dorsal root ganglion sensory neurons and it is activated by the endogenous peptides, cortistatin and proadrenomedullin N-terminal peptide. Here, we show that morphine but not opioid peptides stimulated a dose-dependent increase of the intracellular calcium ion level in MrgX2-expressing cells. Naloxone, an opioid receptor antagonist, did not influence these reactions. It was previously reported that the μ -opioid receptor did not show morphine dependent desensitization and internalization. In contrast, we detected morphine induced MrgX2 desensitization and internalization. Since MrgX2 gave a similar EC_{50} value for morphine with the μ - and δ -opioid receptors, we consider that MrgX2 could be the physiological morphine receptor. It was reported that some morphine effects (e.g. morphine-induced hyperalgesia) were observed even in the presence of an opioid receptor antagonist. Therefore, we propose the importance of studying MrgX2 together with the classical opioid receptors for the investigation of morphine effects.

Key words: morphine, G protein-coupled receptor, MrgX2, desensitization, internalization.

INTRODUCTION

Morphine is well known as a useful clinical agent for analgesia, although it causes serious side effects and physical dependence. Despite extensive investigations, the molecular mechanisms of morphine tolerance are not completely understood. Morphine is an exogenous opioid and it has been revealed to act on μ -, δ - and κ -opioid receptors, which belong to the family of G protein-coupled receptors (GPCRs) (Matthes et al., 1996; Sora et al., 1997; Narita et al. 2001). The morphine effects such as analgesia, tolerance and addiction are mediated mainly via the μ -opioid receptor. However, the molecular effects

of morphine remain to be investigated under high-dose or chronically exposed conditions. Further, the reason why only morphine and not endogenous opioid peptides (e.g., enkephalins and endorphins) shows tolerance remains to be elucidated. A possible speculation is that the classical opioid receptors are not unique receptors for morphine and that there are unknown molecular mechanisms that specifically function for morphine.

MrgX2 was originally identified as an orphan GPCR by human genome analysis. It belongs to a receptor subfamily encoded by mas-related genes (MrGs) that include more than 30 genes of mouse (MrgAs-MrgH) (Han et al., 2002) and approximately 10 genes of humans (MrgD- MrgG and MrgX1-MrgX7) (Dong et al., 2001; Lembo et al., 2002; Choi and Lahn, 2003; Grazzini et al., 2004). It was reported that the Mrg genes are expressed in the dorsal root ganglion (DRG) sensory neurons (Dong et al., 2001; Lembo et al., 2002; Robas et al., 2003). Thus, MrgXs in humans have also been termed as sensory neuron-specific receptors (SNSRs). MrgX2 is expressed not only in DRG neurons but also in a few other tissues such as neurohypophysis, blood vessels, e. t. c. (Allia et al., 2005). Some of the specific ligands for the Mrg receptors

*Corresponding author. E-mail: stakeda@bce.gunma-u.ac.jp.
Tel/Fax: +81-277-30-1434.

Abbreviations

BSA; bovine serum albumin, **CHO**; Chinese hamster ovary, **DRG**; dorsal root ganglion, **FBS**; fetal bovine serum, **GPCR**; G protein-coupled receptor, **Mrg**; mas-related genes, **PAMP**; proadrenomedullin N-terminal peptide, **PCR**; polymerase chain reaction.

have been identified and characterized using cells stably expressing these receptors. For example, MrgA1 and MrgA4 in mouse are activated by RFamide neuropeptides (Han et al., 2002) and MrgX1 (SNSR4) and MrgX7 (SNSR3) in humans are activated by bovine adrenal medulla 22 (BAM22) peptide (Lembo et al., 2002). Recently, cortistatin (Robas et al., 2003) and proadrenomedullin N-terminal peptide (PAMP) (Kamohara et al., 2005) have been identified as endogenous ligands for MrgX2. We previously reported the screening of MrgX2 ligands by using an MrgX2-G ; fusion protein expressed by Sf9 cells and found that dextrorphan and 3-methoxy morphanin, which are morphine analogs, activated MrgX2 (Takeda et al., 2003).

The aim of this paper is characterization of MrgX2 in the view of the morphine receptor. Here, we report that morphine activates MrgX2 under relatively high concentration conditions. We also present the desensitization and internalization of MrgX2 by morphine. Our results and the fact that MrgX2 is expressed in DRG neurons (Robas et al., 2003) suggested that MrgX2 could be also candidate for physiological morphine receptor as well as the classical opioid receptors.

MATERIALS AND METHODS

Materials

Cortistatin, PAMP, -endorphin and leucine-enkephalin were purchased from Peptide Institute. Morphine was purchased from Shionogi. Morphine derivatives, dextrorphan and 3-methoxy morphanin, were purchased from Sigma.

Plasmid construction

To express human MrgX2 in CHO cells, we used a pCDNA4-His/Max B expression vector (Invitrogen) that carries zeocin resistant gene for a selection marker and Xpress-tag sequence after initiation codon for antibody labeling. To assist the translocation of the expressed receptor to cell membranes, N-terminal 20 residues of bovine rhodopsin was added to MrgX2. The cDNA corresponding to the rhodopsin sequence was synthesized and inserted using *EcoRI* and *Not I* sites, resulted in formation of pCDNA4-rhod20 expression vector. The open reading frame of MrgX2 was amplified from human genomic DNA (Clontech) as a template by polymerase chain reaction (PCR) using primers; 5'-AAAGCGGCCGCATGGATCCAACCAACCCCG-3' as a forward primer and 5'-AAATCTAGACTACACCAGACTGCT TCTCGACATC-3' as a reverse primer. PCR condition was 30 cycles of 95°C for 5 s, 60°C for 15 s, 68°C for 30 s by using KOD plus polymerase (TOYOBO) . Resulted PCR product was cloned into pCDNA4-rhod20 vector using *NotI* and *XbaI* sites. Eventually, this pCDNA4-MrgX2 coded a fusion construct of Xpress-tag and rhodopsin N-terminal sequence upstream of human MrgX2. The DNA sequences of all constructs were confirmed by a DNA sequence ABI310 analysis system (Applied Biosystems).

Cell culture and transfection

The CHO-K1 cells were cultured in 100-mm dishes in F-12 Ham

medium (Sigma) containing 10% fetal bovine serum (FBS) at 37°C in 5% CO₂. The CHO-K1 cells were transfected with pCDNA4-MrgX2 using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. After selection of stable transfectants by using 400 g/ml zeocin (Invitrogen), we screened 12 cortistatin-responsive clones by measuring their calcium mobilization as described below. The clone showing the highest potency for cortistatin was used for the subsequent experiments (CHO/MrgX2).

Measurement of calcium mobilization

Measurement of intracellular calcium mobilization was performed as described previously (Obinata et al., 2005). CHO/MrgX2 cells were seeded into black 96-well plates with clear-bottom at a density of 1×10^5 cells/well in 75 μ l medium (F-12 Ham/10%FBS). After the cells were cultured for 24 h at 37 in 5% CO₂, 75 μ l of Hepes-tyrode buffer (25 mM Hepes/NaOH (pH7.4), 140 mM NaCl, 2.7mM KCl, 1 mM CaCl₂, 12 mM NaHCO₃, 0.49 mM MgCl₂, 0.37 mM NaH₂PO₄, 5.6 mM D-glucose, 0.1% bovine serum albumin (BSA)) containing 5 μ M Fura-2 AM (Dojin), 2.5 mM probenecid (Sigma), 0.04% F-127(Sigma) was added into each well. After incubation for 1 h at 37°C in 5% CO₂, the cells were washed with 80 μ l of Hepes-tyrode buffer and then 80 μ l of same buffer was added into each well. Ligands were diluted to the appropriate concentration in Hepes-tyrode buffer containing 5% BSA. Intracellular calcium concentrations were measured using FlexStationII fluorometric imaging plate reader (Molecular Device). For dose-response studies, all data points were carried out in six independent wells.

For measurement of desensitization, conventional fluorescence measurements were done using spectrofluorometer (RF-5300PC, Shimadzu) in glass tubes. CHO/MrgX2 (1×10^7 cells) were harvested and incubated in 10 ml Hepes-tyrode buffer containing 5 μ M Fura-2 AM, 1.25 mM probenecid, 0.02% F-127 for 1 h at 37°C in 5% CO₂. After centrifugation at 1000 rpm for 5 min, cells were resuspend in 8 ml Hepes- tyrode buffer. Intracellular calcium mobilization measured using 600 μ l of cell suspension and 6 μ l of ligand solution were added. The second ligand was added 5 min after the first ligand stimulation and alteration of calcium mobilization were measured.

Fura- 2 fluorescence was measured with excitation at 340 and 380 nm and emission at 510 nm. The fluorescence intensity ratio, I_{340}/I_{380} , was utilized to determine intracellular calcium mobilization. The mock transfected CHO-K1 cells were used for control experiments. All ligands were dissolved in Hepes-tyrode buffer.

Enzyme linked immunosorbent assay (ELISA) for detection of cell surface receptors

For quantification of receptor internalization, amounts of receptors on a cell surface were evaluated by ELISA. CHO/MrgX2 (5×10^3 cells) were plated on 96-well plate in 100 l F-12 Ham/10% FBS medium and incubated for 24 h at 37°C, 5% CO₂. The medium was removed and fresh medium was added into each well. Then, an MrgX2 agonist was added to each well (final concentration of 1 M cortistatin or 100 M morphine) and incubated for indicated times at 37°C, 5% CO₂. After washing with 100 μ l of PBS for three times, the cells were fixed with 4% formaldehyde for 30 min. Cells were washed again with PBS, nonspecific binding was blocked with 1% BSA/PBS for 1 h at room temperature. The cells were labeled with anti-Xpress antibodies and horseradish peroxidase-conjugated anti-mouse IgG antibodies (Promega) diluted to 1:5000 with 1% BSA in PBS and then washed with 0.1% BSA in PBS for three times. The colorimetric reaction was initiated using 100 μ l of a TMB substrate solution (Promega) for peroxidase and was stopped by adding 10 l 0.1M HCl. The absorbance at 450 nm was measured using a microplate reader (Model 680, Bio-Rad).

Table 1. The EC₅₀ values for the agonists of MrgX2.

Ligand	EC ₅₀
Cortistatin	78 ± 19 nM
PAMP	500 ± 130 nM
Somatostatin	350 ± 100 nM
Morphine	4.5 ± 1.7 μM
Dextrorphan	1.4 ± 1.1 μM
3-methoxy morphanin	4.7 ± 2.1 μM
Leucin-enkephalin	>100 μM
-endorphin	>100 μM

The EC₅₀ values for the agonists of MrgX2 determined by the intracellular calcium mobilization assay. All data points represent average of independent triplicate measurements. The intracellular calcium mobilization was measured in fura-2-loaded CHO/MrgX2 cells using FLEXstation II. Each EC₅₀ represents the mean ± SEM of three determinations.

Immunolocalization by fluorescence microscopy

CHO/MrgX2 cells (1×10^5) were grown on a 35 mm glass -based plate at 37°C in 5% CO₂. After 10 min stimulation with 1 μM cortistatin or 100 μM morphine, the cells were fixed with 4% formaldehyde, permeabilized with 0.1% saponin and incubated with 1% BSA in PBS for 1 h at room temperature to block non-specific antibody binding. Antibody staining was performed by incubation with anti-Xpress antibodies (Invitrogen) and following Alexa 488-conjugated anti-mouse IgG antibodies (Molecular Probes) diluted to 1:200 with 1% BSA in PBS. The cells were analyzed under a fluorescence microscope (Axiovert, Carl Zeiss) and by using the imaging software (Axiovision, Carl Zeiss).

RESULTS

First, we examined ligand-dependent calcium mobilization in CHO/MrgX2 cells. We observed significant calcium mobilization when the CHO/MrgX2 cells were stimulated with cortistatin, PAMP and somatostatin with EC₅₀ values of 78, 500 and 350 nM, respectively. Morphine and its derivatives showed less potent activation of MrgX2. The EC₅₀ values determined for morphine, dextrorphan and 3-methoxy morphanin were 4.5, 1.4 and 4.7 M, respectively. Since the maximum response of morphine was approximately 80% of that of cortistatin, morphine influenced MrgX2 as a partial agonist (Figure 1). The activation of MrgX2 by morphine was not affected after 10 min pre- incubation with 100 M naloxone, a nonspecific classical opioid receptor antagonist (data not shown). In contrast, leucine-enkephalin and -endorphin, which are endogenous opioid peptides, did not activate MrgX2 (Table 1).

Next, we examined the desensitization of MrgX2 by stimulation with saturated concentrations of cortistatin (1 M) and morphine (100 M). Although initial stimulation with cortistatin induced a large mobilization of calcium ions, the addition of another cortistatin after 5 min did not induce any response in the CHO/MrgX2 cells (Figure 2a).




Figure 1. Representative results of intracellular calcium mobilization in CHO/MrgX2 cells induced by cortistatin (closed circles), morphine (open circles), dextrorphan (closed squares), and 3-methoxy morphanin (open squares). The Fura-2 fluorescence was measured with excitation at 340 nm and 380 nm, and emission at 510 nm. The fluorescence intensity ratio, I₃₄₀/I₃₈₀, was evaluated to be intracellular calcium mobilization. Each point represents the average

± standard deviation of six determinations (n = 6), and is representative of at least three independent experiments. Mock-transfected cells did not respond to all ligands including Table 1 (data not shown).

This result indicated that MrgX2 was desensitized at the first cortistatin stimulation. When a second stimulation was performed with morphine, no peak was observed (Figure 2b). These results indicated that cortistatin and morphine shared the same receptor MrgX2. We also examined the desensitization of MrgX2 following activation with morphine. Initial morphine stimulation induced calcium mobilization; a subsequent cortistatin or morphine stimulation after 5 min resulted in weak responses in CHO/MrgX2 cells (Figures 2c and 2d). Thus, both cortistatin and morphine desensitized MrgX2 expressed in the CHO cells, although the degree of desensitization by morphine was less than that by cortistatin.

The amount of MrgX2 on the cell surface was quantitatively analyzed by ELISA. Cortistatin (1 M) induced a decrease in the amount of MrgX2 on the cell surface to 78 and 62% after 10 and 120 min of the ligand treatment, respectively (Figure 3). The amount of MrgX2 on the cell surface was also decreased to 83 and 64% after stimulation with 100 M morphine for 10 and 120 min, respectively. We also observed the ligand-treated CHO/MrgX2 cells under a fluorescence microscope. The plasma membranes were stained uniformly in untreated cells, suggesting that the MrgX2 receptors expressed homogeneously on the plasma membrane prior to ligand stimulation (Figure 4a). After stimulation with 100 M morphine for 10 min, the cells showed several intracellular punctuate fluorescence and bright vesicles (Figure 4b). This result suggested that the receptor of morphine treated




Figure 2. Cortistatin (1 M) and morphine (100 M) produced rapid desensitization of MrgX2. Time course of intracellular calcium mobilization in Fura-2- loaded CHO/MrgX2 cells is shown. The second ligand (A and C; cortistatin, B and D; morphine) was added 5 min after the stimulation with the first ligand (A and B; cortistatin, C and D; morphine), and alterations in calcium mobilization were measured. Adenosine 5'- triphosphate (1 M) was also added 5 min after the administration of the second ligand to confirm that heterologous desensitization did not occurred. The Fura-2 fluorescence was measured with excitation at 340 nm and 380 nm, and emission at 510 nm. The fluorescence intensity ratio, I₃₄₀/I₃₈₀, was evaluated to be intracellular calcium mobilization.

cells were internalized as well as 1 M cortistatin-treated cells (Figure 4c) . Therefore, we considered that the ligand-dependent loss of MrgX2 from the cell surface resulted from receptor internalization.

DISCUSSION

CHO/MrgX2 cells were stimulated not only by cortistatin and PAMP but also by morphine and its derivatives. In contrast, leucine-enkephalin and -endorphin, which are endogenous opioid peptides, did not activate MrgX2. The plasma concentration of morphine after clinical administration is approximately 10 nM (Collins et al., 1998). Since the EC₅₀ values of morphine for the μ - opioid receptor and MrgX2 are 17 nM (Gharagozlu et al., 2003) and 4.5 M, respectively, it is reasonable to consider that MrgX2 does not possess physiological functions for morphine under normal conditions. However, the plasma concentration of morphine is assumed to be higher than that of the normal clinical value under chronic treatment, development of tolerance and addictive condition. To understand the functions of morphine under relatively high concentrations, several investigations have been carried out for additional morphine receptors.

One candidate for the additional morphine receptor is the δ -opioid receptor that shows an EC₅₀ value of 1.0 M for morphine (Gharagozlu et al., 2002). In addition, it is reported that the δ -opioid receptor is involved in morphine tolerance and dependence (Zhu et al., 1999; Pradhan et al., 2006; Zhang et al., 2006; Narita et al., 2001). In our experiment, the EC₅₀ value of MrgX2 for morphine was 4.5 M; this value was higher but almost equal to that of the δ -opioid receptor. Not only the δ -opioid receptor but also the μ -opioid receptor was considered to be the physiologically functional morphine receptor because a high concentration of morphine induced analgesia through the μ -opioid receptor in the μ -opioid receptor knockout mice (Yamada et al., 2006). According to these facts, we consider that MrgX2 could be physiological morphine receptor as well as the μ - and δ - opioid receptors. We are also interested in the evidences for unknown morphine receptors have been reported. Morphine-induced hyperalgesia, for example, was observed even when all the three types of opioid receptors were blocked simultaneously by using naltrexone (Wu et al., 2004; Juni et al., 2006). In the immune system, immunosuppression induced by morphine occurred via the naloxone-insensitive receptor (Roy et al., 1998).

In our experiments, MrgX2 was completely desensitized after stimulation with cortistatin (Figures 2A and 2B) . On the other hand, the remaining weak response for morphine was observed even after morphine stimulation (Figures 2c and 2d). These results were consistent with our assumption that morphine was a partial agonist for MrgX2 (Kovoor et al., 1998). The tolerance for morphine is partly explained by receptor desensitization and internalization




Figure 3. Representative results of MrgX2 receptor internalization induced by 1 M cortistatin or 100 M morphine; cortistatin (open circles), morphine (closed squares), and buffer control (closed circles). The percentage of MrgX2 receptors remaining on the cell surface after agonist stimulation were measured by ELISA analysis. Each point represents the average of two determinations ($n = 2$), and is representative of at least three independent experiments. *Significantly different from the control group receiving the buffer instead of morphine. Analysis of variance, Student's test, $p < 0.05$.




Figure 4. Fluorescence observations of the agonist-induced MrgX2 internalization. (A), no stimulation with a ligand; (B), after 10 min stimulation with 100 M morphine; (C), after 10 min stimulation with 1 M cortistatin.

(Bailey and Connor 2005; Narita et al., 2006). Thus, the difference in the degree of desensitization between endogenous peptides and morphine should be considered in order to understand morphine tolerance not only for opioid receptors but also for MrgX2. Moreover, it is reported that the μ -opioid receptor does not show morphine dependent desensitization and internalization (Keith et al., 1996; Minnis et al., 2003) in contrast with MrgX2. Based on the above discussion, we propose the importance of studying MrgX2 together with the classical opioid receptors for the investigation of the morphine effects.

MrgX2 belongs to the Mrg subfamily. The homologies of amino acid sequences between MrgXs and opioid receptors are low. However, the fact that morphine activates MrgX2 and BAM22 (a proenkephalin A gene product) activates MrgX1 (SNSR4) and MrgX7 (SNSR3) (Lembo et al., 2002) suggests that MrgX members are functionally similar to opioid receptors. In addition, both MrgXs and opioid receptors are expressed in DRG neurons and could work together for modulation of nociception. Further investigations will clarify the physiological relationship between opioid receptors and MrgXs.

ACKNOWLEDGMENT

This work was supported by a grant-in-Aid to S. T. for Scientific Research on Priority Areas (No. 16048202) from The Ministry of Education, Culture, Sports, Science and Technology (MEXT).

REFERENCES

- Allia E, Tarabra E, Volante M, Cerrato M, Ghigo E, Muccioli G, Papotti M (2005) Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours. *J. Pathol.* 207: 336-345.
- Bailey CP, Connor M (2005). Opioids: cellular mechanisms of tolerance and physical dependence. *Curr Opin Pharmacol.* 5: 60-68.
- Choi SS, Lahn BT (2003). Adaptive evolution of MRG, a neuron-specific gene family implicated in nociception. *Genome Res.* 13: 2252-2259.
- Collins SL, Faura CC, Moore RA, McQuay HJ (1998). Peak plasma concentrations after oral morphine: a systematic review. *J. Pain Symptom Manage.* 16: 388-402.
- Dong X, Han S, Zylka MJ, Simon MI, Anderson D (2001). A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. *Cell.* 106: 619-632.
- Gharagozlou P, Demirci H, Clark JD, Lameh J (2002). Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors. *BMC Neurosci.* 3: 19.
- Gharagozlou P, Demirci H, David CJ, Lameh J (2003). Activity of opioid ligands in cells expressing cloned mu opioid receptors. *BMC Pharmacol.* 3: 1.
- Grazzini E, Puma MC, Roy O, Yu XH, O'Donnell D, Schmidt R, Dautrey S, Ducharme J, Perkins M, Panetta R, Laird JM, Ahmad S, Lembo PM (2004). Sensory neuron-specific receptor activation elicits central and peripheral nociceptive effects in rats. *Proc. Natl. Acad. Sci. U.S.A.* 101: 7175-7180.
- Han SK, Dong X, Hwang JI, Zylka MJ, Anderson DJ, Simon MI (2002). Orphan G protein-coupled receptors MrgA1 and MrgC11 are

- distinctively activated by RF-amide-related peptides through the Galpha q/11 pathway. *Proc. Natl. Acad. Sci., U.S.A.* 99: 14740-14745.
- Juni A, Klein G, Kest B (2006). Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems. *Brain Res.*, 1070: 35-44.
- Kamohara M, Matsuo A, Takasaki J, Kohda M, Matsumoto M, Matsumoto S, Soga T, Hiyama H, Kobori M, Katou M (2005). Identification of MrgX2 as a human G-protein-coupled receptor for proadrenomedullin N-terminal peptides. *Biochem Biophys Res. Commun.*, 330: 1146-1152.
- Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, von Zastrow M (1996). Morphine activates opioid receptors without causing their rapid internalization. *J. Biol. Chem.*, 271: 19021-19024.
- Kovoor A, Celver JP, Wu A, Chavkin C (1998). Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. *Mol. Pharmacol.*, 54: 704-711.
- Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J, Hoffert C, Cao J, Schmidt R, Pelletier M, Labarre M, Gosselin M, Fortin Y, Banville D, Shen SH, Strom P, Payza K, Dray A, Walker P, Ahmad S (2002). Proenkephalin A gene products activate a new family of sensory neuron-specific GPCRs. *Nat. Neurosci.*, 5: 201-209.
- Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature*, 383: 819-823.
- Minnis JG, Patierno S, Kohlmeier SE, Brecha NC, Tonini M, Sternini C (2003). Ligand-induced mu opioid receptor endocytosis and recycling in enteric neurons. *Neurosci.*, 119: 33-42.
- Narita M, Funada M, Suzuki T (2001). Regulations of opioid dependence by opioid receptor types. *Pharmacol. Ther.*, 89: 1-15.
- Narita M, Suzuki M, Narita M, Niikura K, Nakamura A, Miyatake M, Yajima Y, Suzuki T (2006). Mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine. *Neuroscience*, 138: 609-619.
- Obinata H, Hattori T, Nakane S, Tatei K, Izumi T (2005) Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. *J. Biol. Chem.*, 280: 40676-40683.
- Pradhan AA, Siau C, Constantin A, Clarke PB (2006). Chronic morphine administration results in tolerance to delta opioid receptor-mediated antinociception. *Neuroscience*, 141: 947-954.
- Robas N, Mead E, Fidock M (2003). MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion. *J. Biol. Chem.*, 278: 44400-44404.
- Roy S, Barke RA, Loh HH (1998). MU-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. *Mol. Brain. Res.*, 61: 190-194.
- Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997). Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. *Proc. Natl. Acad. Sci. U.S.A.*, 94: 1544-9154.
- Takeda S, Yamamoto A, Okada T, Matsumura E, Nose E, Kogure K, Kojima S, Haga T (2003). Identification of surrogate ligands for orphan G protein-coupled receptors. *Life Sci.*, 74: 367-377.
- Wu HE, Thompson J, Sun HS, Leitermann RJ, Fujimoto JM, Tseng LF (2004) Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord. *J. Pharmacol. Exp. Ther.*, 310: 240-246.
- Yamada H, Shimoyama N, Sora I, Uhl GR, Fukuda Y, Moriya H, Shimoyama M (2006). Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors. *Brain Res.*, 1083: 61-69.
- Zhang X, Bao L, Guan JS (2006). Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance. *Trends Pharmacol. Sci.*, 27: 324-329.
- Zhu Y, King MA, Schuller AG, Nitsche JF, Reidl M, Elde RP, Unterwald E, Pasternak GW, Pintar JE (1999). Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. *Neuron*, 24: 243-252.